tRNA therapeutics for genetic diseases
- PMID: 38049504
- DOI: 10.1038/s41573-023-00829-9
tRNA therapeutics for genetic diseases
Abstract
Transfer RNAs (tRNAs) have a crucial role in protein synthesis, and in recent years, their therapeutic potential for the treatment of genetic diseases - primarily those associated with a mutation altering mRNA translation - has gained significant attention. Engineering tRNAs to readthrough nonsense mutation-associated premature termination of mRNA translation can restore protein synthesis and function. In addition, supplementation of natural tRNAs can counteract effects of missense mutations in proteins crucial for tRNA biogenesis and function in translation. This Review will present advances in the development of tRNA therapeutics with high activity and safety in vivo and discuss different formulation approaches for single or chronic treatment modalities. The field of tRNA therapeutics is still in its early stages, and a series of challenges related to tRNA efficacy and stability in vivo, delivery systems with tissue-specific tropism, and safe and efficient manufacturing need to be addressed.
© 2023. Springer Nature Limited.
Similar articles
-
Translation velocity determines the efficacy of engineered suppressor tRNAs on pathogenic nonsense mutations.Nat Commun. 2024 Apr 5;15(1):2957. doi: 10.1038/s41467-024-47258-9. Nat Commun. 2024. PMID: 38580646 Free PMC article.
-
Optimization of ACE-tRNAs function in translation for suppression of nonsense mutations.Nucleic Acids Res. 2024 Dec 11;52(22):14112-14132. doi: 10.1093/nar/gkae1112. Nucleic Acids Res. 2024. PMID: 39673265 Free PMC article.
-
Therapeutic promise of engineered nonsense suppressor tRNAs.Wiley Interdiscip Rev RNA. 2021 Jul;12(4):e1641. doi: 10.1002/wrna.1641. Epub 2021 Feb 10. Wiley Interdiscip Rev RNA. 2021. PMID: 33567469 Free PMC article. Review.
-
AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice.Nature. 2022 Apr;604(7905):343-348. doi: 10.1038/s41586-022-04533-3. Epub 2022 Mar 23. Nature. 2022. PMID: 35322228 Free PMC article.
-
Mechanisms and Delivery of tRNA Therapeutics.Chem Rev. 2024 Jun 26;124(12):7976-8008. doi: 10.1021/acs.chemrev.4c00142. Epub 2024 May 27. Chem Rev. 2024. PMID: 38801719 Free PMC article. Review.
Cited by
-
Application Strategies of Super-Enhancer RNA in Cardiovascular Diseases.Biomedicines. 2025 Jan 7;13(1):117. doi: 10.3390/biomedicines13010117. Biomedicines. 2025. PMID: 39857701 Free PMC article. Review.
-
Suppressor tRNA in gene therapy.Sci China Life Sci. 2024 Oct;67(10):2120-2131. doi: 10.1007/s11427-024-2613-y. Epub 2024 Jun 24. Sci China Life Sci. 2024. PMID: 38926247 Review.
-
Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation.Nucleic Acid Ther. 2024 Apr;34(2):52-72. doi: 10.1089/nat.2023.0068. Epub 2024 Mar 20. Nucleic Acid Ther. 2024. PMID: 38507678 Free PMC article. Review.
-
Preventing vision loss in a mouse model of Leber Congenital Amaurosis by engineered tRNA.bioRxiv [Preprint]. 2025 Jul 11:2025.07.10.660754. doi: 10.1101/2025.07.10.660754. bioRxiv. 2025. PMID: 40672310 Free PMC article. Preprint.
-
tRNA and tsRNA: From Heterogeneity to Multifaceted Regulators.Biomolecules. 2024 Oct 21;14(10):1340. doi: 10.3390/biom14101340. Biomolecules. 2024. PMID: 39456272 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources